Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01805687 · ClinicalTrials.gov registry record · Phase 4
Single Dose Bronchodilatory Study in Asthma
A Phase 4 study of Asthma, sponsored by Cornerstone Therapeutics.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01805687: Completed Phase 4 study of Asthma, sponsored by Cornerstone Therapeutics.
NCT01805687 is a Phase 4 study of Asthma that has completed, run by Cornerstone Therapeutics. The registered enrollment target is 25 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01805687, a Phase 4 study of Asthma, has completed, sponsored by Cornerstone Therapeutics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Study to evaluate the bronchodilator effects of Zyflo CR in patients with chronic stable asthma.
Conditions Studied
Interventions
- DRUG Zileuton extended release
Study Locations (1)
Massachusetts
- Northeast Medical Research Associates - North Dartmouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2013-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01805687
The ClinicalTrials.gov registry entry for NCT01805687 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower). The listed sponsor is Cornerstone Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Zileuton extended release is the first listed.
NCT01805687 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01805687 about?
NCT01805687 is a clinical study titled "Single Dose Bronchodilatory Study in Asthma". Study to evaluate the bronchodilator effects of Zyflo CR in patients with chronic stable asthma.
What is the current status of trial NCT01805687?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2013-03.
What conditions does trial NCT01805687 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT01805687?
The interventions under investigation include: Zileuton extended release (DRUG).
Who is sponsoring clinical trial NCT01805687?
This trial is sponsored by Cornerstone Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01805687 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.